BlueCross BlueShield Federal Employee Program

VITRAKVI
(larotrectinib)

Pre - PA Allowance

None

Prior-Approval Requirements

Diagnosis

Patient must have the following:

Solid tumors with neurotrophic receptor kinase (*NTRK*) gene fusion

AND ALL of the following:

1. Presence of *NTRK* gene fusion has been detected by an FDA-approved test
2. Solid tumors are metastatic **OR** surgical resection is likely to result in severe morbidity
3. There are no satisfactory alternative treatments **OR** disease has progressed following treatment
4. **NONE** of the following acquired resistance point mutations:
    a. G595R
    b. G623R
    c. G696A
    d. F617L
5. Prescriber agrees to monitor AST and ALT
6. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Vitrakvi and for 1 week after the final dose

Prior - Approval Limits

Quantity *2*00 mg per day

Duration 12 months

Prior – Approval *Renewal* Requirements

Diagnosis

Patient must have the following:

Solid tumors with neurotrophic receptor kinase (*NTRK*) gene fusion

AND ALL of the following:

1. **NO** disease progression or unacceptable toxicity
2. Prescriber agrees to monitor AST and ALT
3. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Vitrakvi and for 1 week after the final dose

Prior - Approval *Renewal* Limits

Same as above